Advertise on podcast: MedEdTalks - Pulmonology

Description

MedEdTalks Pulmonology is a continuing medical education podcast for physicians to allow them to learn while on the go and obtain CME credits. The intended audience for this show is pulmonologists, internists, rheumatologists and other health care professionals.

Unlock MedEdTalks - Pulmonology podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from MedEdTalks - Pulmonology podcast

The Importance of Patient Education on Adherence to Therapies in IPF with Drs. Robert J. Kaner and Maria Padilla

2022/02/25

In this podcast, expert clinicians will discuss best practice for improving patient-provider communication to improve adherence to IPF therapies.

Long-term Outcomes with IPF Therapies with Drs. Maria Padilla and Steven D. Nathan, MD

2022/02/25

In this podcast, expert clinicians will discuss the most recent data regarding long-term outcomes with current therapies for IPF.

The Importance of Early and Accurate Diagnosis in IPF with Drs. Maria Padilla and Robert J. Kaner

2022/02/25

In this podcast, expert clinicians will discuss evidence-based best practices for making early and accurate diagnoses in IPF.

Improving Adherence: Patient Engagement and Education With Drs. Elizabeth R. Volkmann and Kristin B. Highland

2021/08/20

In this podcast, expert clinicians will discuss the strategies to improve patients adherence to therapy in SSc-ILD.

Management of SSc-ILD: Guidelines and Treatment Options With Drs. Elizabeth R. Volkmann and Kevin R. Flaherty

2021/08/20

In this podcast, expert clinicians will discuss evidence-based recommendations for the treatment of SSc-ILD.

Diagnosis of SSc-ILD: Screening and Monitoring of Lung Function With Drs. Elizabeth R. Volkmann and Kristin B. Highland

2021/08/20

In this podcast, expert clinicians will discuss best practices in the diagnosis of SSc-ILD.

Understanding SSc-ILD: Prevalence and Burden of Disease With Drs. Elizabeth R. Volkmann and Kevin R. Flaherty

2021/08/20

In this podcast, expert clinicians will discuss the prevalence and burden of SSc-ILD.

Treating a Patient With Refractory Nontuberculous Mycobacterial Lung Disease, with Drs. Anne O’Donnell and David Griffith

2020/11/17

In this podcast, expert clinicians will discuss treatment for a patient with refractory Mycobacterium avium complex lung disease despite many months of guidelines-based therapy. For CME Credit, complete activity here: https://tinyurl.com/LungMET2

Managing Mycobacterium Avium Complex Lung Infection in a Patient With Underlying Lung Disease, with Drs. Anne O’Donnell and Angela DiMango

2020/11/17

In this podcast, expert clinicians will discuss treatment for Mycobacterium avium complex lung infection in a patient with underlying granulomatosis with polyangiitis affecting the lungs. For CME Credit, complete activity here: https://tinyurl.com/LungMET1

Dr. Nathan and Dr. Patel Discuss a Challenging Case in Treating PF-ILD

2020/10/22

Interstitial lung disease (ILD) describes a group of over more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (eg, asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss a challenging case on treating a patient with PF-ILD. Transcript: https://tinyurl.com/PF-ILD4Transcript For CME Credit, complete activity here: https://tinyurl.com/PF-ILD4

Dr. Nathan and Dr. Patel Discuss a Challenging Case in Diagnosing PF-ILD

2020/10/22

Interstitial lung disease (ILD) describes a group of over more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (eg, asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss a challenging case on diagnosing a patient with PF-ILD. Transcript: https://tinyurl.com/PF-ILD3Transcript For CME Credit, complete activity here: https://tinyurl.com/PF-ILD3

Dr. Nathan and Dr. Lancaster Discuss a Challenging Case in Treating PF-ILD

2020/10/22

Interstitial lung disease (ILD) describes a group of over more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (eg, asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss a challenging case on treating a patient with PF-ILD. Transcript: https://tinyurl.com/PF-ILD2Transcript For CME Credit, complete activity here: https://tinyurl.com/PF-ILD2